Cancer-associated thrombocytosis has long been linked to poor clinical outcome, but the underlying mechanism is enigmatic. We hypothesized that platelets promote malignancy and resistance to therapy by dampening host immunity. We show that genetic targeting of platelets enhances adoptive T cell therapy of cancer. An unbiased biochemical and structural biology approach established transforming growth factor  (TGF) and lactate as major platelet-derived soluble factors to obliterate CD4 + and CD8 + T cell functions. Moreover, we found that platelets are the dominant source of functional TGF systemically as well as in the tumor microenvironment through constitutive expression of the TGF-docking receptor glycoprotein A repetitions predominant (GARP) rather than secretion of TGF per se. Platelet-specific deletion of the GARP-encoding gene Lrrc32 blunted TGF activity at the tumor site and potentiated protective immunity against both melanoma and colon cancer. Last, this study shows that T cell therapy of cancer can be substantially improved by concurrent treatment with readily available antiplatelet agents. We conclude that platelets constrain T cell immunity through a GARP-TGF axis and suggest a combination of immunotherapy and platelet inhibitors as a therapeutic strategy against cancer.
INTRODUCTION
Platelets, or thrombocytes, play essential roles in hemostasis (1) . Increasingly, they have emerged to possess other regulatory functions in physiology such as angiogenesis, wound healing, and immunomodulation (2) (3) (4) . Intriguingly, cancer-associated thrombocytosis is an independent poor prognostic factor in multiple cancer types (5, 6) , via enhancing invasiveness of cancer cells (7) , promoting cancer motility (4, 8) , and inducing epithelial-mesenchymal cell transi tion (9) . Despite knowledge of platelet cross-talk with natural killer cells (10) , neutrophils (11) , macrophages (12) , dendritic cells (13) (14) (15) , and T lymphocytes (14) , the direct impact of thrombocytes on T cell immunity against cancer and the underlying molecular mechanisms have yet to be fully elucidated.
Platelets are bioactive, anuclear cellular fragments that are shed out of megakaryocytes in the bone marrow vasculature (16) . They are the smallest cellular component of the hematopoietic system and are second only to red blood cells in number. Platelets express a number of cell surface receptors for adhesion and aggregation (1, 17) , such as glycoprotein (GP) Ib-IX-V complex, which serves as a receptor for von Willebrand factor, and GPIIb-IIIa integrin, which binds to fibrinogen and fibronectin. They also express other activation receptors, including the thromboxane A2 receptor, the adenosine diphosphate (ADP) receptors P2Y1 and P2Y12, and the protease-activated receptors PAR1 and PAR4, the latter of which can be activated by thrombin (18) . Platelets have been found to constitutively express the nonsignaling transforming growth factor  (TGF)-docking receptor glycoprotein A repetitions predominant (GARP) (19) , encoded by the leucine-rich repeat-containing protein 32 (Lrrc32) gene. The role of GARP is to increase the activation of latent TGF (LTGF) and thus its biological function in the close proximity of GARP-expressing cells. The other cells that express GARP are regulatory T (T reg ) cells, which do so only after activation via T cell receptor (TCR) (20) . Both GPIb-IX-V complex and GARP depend on the molecular chaperone gp96 for folding and cell surface expression (21, 22) . Genetic deletion of Hsp90b1 (encoding gp96) from platelets results in significant thrombo cytopenia and impaired platelet function (21) . Last, there are cytoplasmic granules in platelets containing a variety of molecules such as TGF, ADP, serotonin, and proteases, which are released upon platelet activation and degranulation to exert their functions (23, 24) .
The key unresolved questions are how platelets affect the adaptive immunity in cancer and what are the underlying molecular mechanisms for such an action. With regard to TGF, it is completely unknown what the physiological function of platelet-specific cell surface GARP-TGF is in host immunity. In addition, GARP-TG-F complex on platelets could be formed intracellularly, during the de novo biogenesis, or extracellularly, where GARP snatches LTG-F in the extracellular matrix from nonplatelet sources and binds to it. However, it is unclear which source of the GARP-TGF complex is critical in regulating the host immunity against cancer in vivo. In this study, we systematically probed the effect of platelets on the effector function of antitumor T cells. We also took an unbiased approach to identify platelet-derived soluble immunoregulatory factors in blunting T cell function. This study not only uncovers mechanisms of platelet-mediated T cell suppression but also demonstrates the validity of the combination therapy of cancer with immunotherapeutics and antiplatelet (AP) agents in clinically relevant mouse models.
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RESULTS
Genetic inhibition of platelets enhances adoptive T cell therapy of cancer
Using bone marrow chimeric mice, we previously demonstrated that genetic deletion of Hsp90b1 from the hematopoietic system resulted in macrothrombocytopenia coupled with dysfunctional platelets due to the loss of cell surface GPIb-IX-V, the receptor for von Willebrand factor (21) . To probe the immunological function of platelets, we generated a megakaryocyte-specific Hsp90b1 knockout (KO) mouse model in this study. As expected, KO mice had significantly lower platelet counts in the blood compared with wild-type (WT) mice (Fig. 1A) . The dysfunction of platelets was evidenced by prolonged bleeding time (Fig. 1B) . Extensive phenotypical analysis showed no obvious abnormalities in other cellular lineages, including T and B cells in the hematopoietic system of KO mice ( fig. S1, A to D) . The ability of CD8 + and CD4 + cells from the KO mice to produce interferon- (IFN) in response to polyclonal activation was also unaffected (fig. S1, E and F).
Adoptive T cell therapy (ACT) was next used to determine whether platelet dysfunction in the host affects the ability of transferred donor T cells to control cancer. ACT is a process of transferring preactivated antigen-specific T cells for the treatment of established cancers (25) . Melanoma was chosen because (i) immuno therapy of unresectable melanoma has been increasingly implemented over the past few years with encouraging efficacies (26) and (ii) TCR trans genic mice of both CD4 + (TRP1) and CD8 + (Pmel) lineages (27, 28) against melanoma antigens permit studying tumor-reactive T cells in our mouse models. B16-F1 melanomas were therefore established in C57BL/6 mice after subcutaneous injection on day 0, followed by infusion of ex vivo primed Pmel cells on day 11, along with interleukin-2 (IL-2)-anti-IL-2 antibody complex (29) . Transferred Pmel cells had better antitumor activity in the Hsp90b1 KO recipients compared with WT ones (Fig. 1C) , whereas no difference in tumor growth was observed between the two groups without ACT (Fig. 1D) . The improved ACT efficacy in the KO mice was associated with increased production of IFN (Fig. 1E ) and tumor necrosis factor- (TNF) (Fig. 1F) by the donor T cells. These results suggest that platelet function in tumorbearing mice constrains T cell-mediated cancer immunotherapy.
Platelet releasate suppresses T cell activation and function
We next focused on understanding the molecular mechanisms of T cell suppression by platelets. Given that platelets are not usually found in the lymphatic system and the T/B cell zone of the lymphoid organs, we reasoned that activated platelets exert their immunosuppressive function via releasing soluble factors. Purified platelets were suspended at 10 8 platelets/ml (several times lower than physiological platelet concentration) and activated with thrombin to generate platelet releasate (PR). The suppressive capacity was then measured in vitro using a standard polyclonal T cell activation assay ( fig. S2A ). Soluble factors in PR, but not platelet microvesicles (MVs), completely blocked T cell proliferation, blastogenesis, and IFN production ( Fig. 2 and fig. S2 , B to G). The activity of PR was not species-specific because both mouse ( Fig. 2A) and human ( Fig. 2B ) PRs suppressed the activation and effector function of T cells from either source. Several parameters related to PR-mediated T cell suppression were also examined (fig. S3, A to J). The negative effect of PR could not be rescued by highdose IL-2 ( fig. S3A ). Kinetic studies showed that the inhibitory effect was most pronounced during the first 2 days of T cell activation and was irreversible ( fig. S3 , B to G). Supernatant from unstimulated platelets had minimal effects ( fig. S3H ). PR had no direct effect on the proliferation of nonlymphocytes such as fibroblasts and B16-F1 melanoma ( fig. S3, I and J). In addition, PR-treated T cells displayed a naïve phenotype expressing more CD62L and less CD44, programmed death-1 (PD-1), glucocorticoid-induced TNF receptor-related protein (GITR), and CD25 (Fig. 2, C and D) . Moreover, the presence of PR during in vitro activation of CD4 + TRP1 transgenic T helper 17 (T H 17) cells (27) abolished their activity upon adoptive transfer against B16-F10 melanoma (Fig. 3A) and reduced their persistence in the recipient mice (Fig. 3B) . Similarly, CD8 + Pmel cells also lost their antitumor activity in the adoptive transfer setting after exposure to PR during ex vivo activation (Fig. 3C ), which correlated with poor donor cell persistence (Fig. 3D) .
Platelet TGF and lactate mediate T cell suppression Next, we took an unbiased approach to identify active T cell-suppressive molecule(s) in the PR. Human PR was fractionated by size exclusion chromatography, followed by quantifying individual fractions for their suppressive activity. Two major peaks with suppressive activity were resolved (Fig. 4A) . Fraction A (>150 kDa) was further subfractionated by anion exchange chromatography (Fig. 4B) . Coomassie blue staining of a reducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of the most active subfractions showed prominent bands corresponding to 150 to 250 kDa and 10 to 50 kDa (Fig. 4B ). Mass spectrometry identified these proteins to be mature TGF (mTGF), latency-associated peptide (LAP), LTGF-binding protein 1 (LTBP1), and thrombospondin-1 (TSP1), indicating the presence of an mTGF-LAP-LTBP1-TSP1 complex (30) . Immunoblot confirmed the existence of mature (12.5 kDa) and latent (44 kDa) TGF, LTBP1 (180 kDa), and TSP1 (110 to 180 kDa) in the whole PR, as well as in fraction A (Fig. 4B ). Neutralizing TGF with the combination of an inhibitor for activin receptor-like kinase 5 (ALK5) (also known as type I TGF receptor) and anti-TGF antibody in fraction A completely rescued T cell function (Fig. 4C) . We thus defined TGF as a major T cell-suppressive factor in the PR. However, blocking TGF in the whole mouse PR only partially rescued T cell activity in vitro ( fig. S4 ), indicating the presence of other TGF-independent factors. Furthermore, the activity of fraction B in both human and mouse PRs was heat-stable, proteinase K-resistant, and smaller than 1.0 kDa in size ( fig. S5) . Fraction B was then subfractionated by an anion exchange column to obtain subfractions B1 to B8 and used nuclear magnetic resonance (NMR) spectroscopy to delineate the metabolite composition (Fig. 4, D and E) . Targeted profiling using the Chenomx NMR Suite software identified lactate as the most abundant metabolite (~3.4 mM) in the most suppressive B3 and B4 subfractions (Fig. 4E) . The immunoregulatory roles of lactate in T cells (31) and macrophages (32) have been reported. The concentration of lactate in the whole PR was ~5.7 mM. Lactate efficiently suppressed T cell activation with concentrations as low as 2.5 mM (Fig. 4F ). Blocking both TGF (by a neutralizing antibody) and lactic acid (LA) (by inhibiting monocarboxylate transporter I with -cyano-4-hydroxycinnamic acid) (32) in the whole human PR almost completely rescued IFN production, CD25 expression, and blastogenesis of CD8 + T cells ( fig. S6 ). Thus, we conclude that the suppressive activity of PR primarily resides in TGF and lactate.
To further address the suppressive components in the PR, we performed an in vitro T reg induction assay. Splenocytes were activated with anti-CD3/28 antibody in the presence of PR, TGF, and lactate for 3 days. We then investigated whether TGF and/or LA can independently recapitulate the inhibitory effects of PR on tumor-reactive T cells. B16-F1 melanoma tumors were established in C57BL/6 mice, which were subsequently treated with Pmel CD8 T cells, similar to the experiment described in Fig. 3C . T cells were primed ex vivo with human gp100 (hgp100) and IL-12 in control media (Pmel-12), PR, TGF, and/ or LA ( fig. S8 ). T cells primed in the presence of PR or TGF (650 pg/ ml, the concentration of TGF present in PR from 1 × 10 8 platelets/ml) failed to control melanoma progression and to persist in peripheral blood ( fig. S8 , A to C). This poor in vivo persistence is likely explained by the failure of Pmel cells to up-regulate receptors of the homeostatic cytokines IL-2 and IL-7 under these conditions ( fig. S8D ). IL-7 is crucial for Pmel cell persistence in vivo in the Pmel tumor model (33) . In turn, LA in the priming phase had no effect on the subsequent antitumor activity of Pmel T cells. This suggests that plateletderived TGF is likely a more relevant target in immunotherapy.
Platelet-intrinsic GARP plays critical roles in generating active TGF
Platelets not only produce and store high levels of TGF intracellularly (34) but also are the only cellular entity known so far that constitutively expresses the cell surface-docking receptor GARP for TGF (19) . Thus, platelets may contribute to the systemic levels of TGF via active secretion, as well as GARP-mediated capturing from other cells or the extracellular matrix (9, (35) (36) (37) . We next addressed to what extent and how platelets contribute to the physiological TGF pool. Baseline sera were obtained from WT mice followed by administration of a platelet-depleting antibody. These mice were sequentially bled, and serum TGF was quantified by enzyme-linked immunosorbent assay (ELISA). Depletion of platelets resulted in a complete loss of active and total TGF, which rebounded effectively as soon as platelet count recovered (Fig. 5A ). These experiments demonstrate that platelets contribute dominantly to the circulating TGF level. By comparison, serum LA with or without depletion showed no significant changes ( fig. S9 ), arguing that platelet-derived TGF, but not LA, is a more relevant platelet-derived immunosuppressive molecule in vivo.
The biology of platelet-derived TGF in cancer immunity was addressed next, focusing on the role of platelet GARP in the production of active TGF.In addition to platelet-specific Hsp90b1 KO mice, two additional mouse models were generated: one with selective deletion of GARP in platelets (Pf4-cre-Lrrc32 flox/flox or Plt-GARP KO ) and another with platelet-restricted KO of TGF1 (Pf4-cre-Tgfb1 flox/flox or Plt-TGF1 KO ) (Fig. 5B ). Because gp96 is also an obligate chaperone for GARP (22) , platelets from neither Plt-gp96 KO mice nor Plt-GARP KO mice expressed cell surface GARP-TGF complex. However, platelets from Plt-TGF1 KO mice expressed similar levels of surface GARP-TGF1 complex when compared with WT platelets (Fig. 5 , B to D), indicating that the GARP-TGF1 complex can be formed without autocrine TGF1.
The levels of active TGF and LTGF were then measured in the plasma and sera of WT and KO mice (Fig. 5 , E and F). In WT mice, active TGF was elevated in serum compared with plasma, indicating a role for platelets and/or the coagulation cascade in TGF activation (Fig. 5E ). Plt-gp96 KO and Plt-GARP KO mice had very little active TGF in their sera, confirming the importance of platelet-intrinsic GARP in converting LTGF to the active form. In contrast, the serum level of active TGF in Plt-TGF1 KO mice was comparable with that of WT mice (Fig. 5E ), indicating that platelets are capable of activating TGF from nonplatelet sources in a trans fashion. Significantly, the total LTGF level in the serum is only reduced in Plt-TGF1 KO mice but not Plt-gp96 KO or Plt-GARP KO mice (Fig. 5F ). Collectively, these data indicate that platelet-intrinsic GARP is the most important mechanism in the activation of TGF systemically. This experiment also categorically confirmed that serum but not plasma level of active TGF reflects platelet activation. conditions, in control media or human PR (n = 6 per group). They were then adoptively transferred on day +10 to B16-F10-bearing mice that also received sublethal dose of total body irradiation on day +9. (B) Percentages of TRP1 cells in the peripheral blood on day +37 (n = 6 to 7 per group). Mann-Whitney test for non-normal distribution was used to compare the two groups. WBC, white blood cell. (C) Pmel T cells were primed with IL-12 and hgp100 peptide, in control media or human PR. They were then adoptively transferred on day +8 to B16-F10-bearing mice that also received cyclophosphamide on day +7 (n = 4 to 8 per group). (D) Percentages of Pmel cells in the peripheral blood on day +33 (n = 4 to 8 per group). Tumor growth curves were compared using repeated-measures two-way ANOVA. Percentages of T cells were compared using two-tailed independent Student's t tests. Data are means ± SEM.
Platelet GARP-TGF complex blunts antitumor T cell immunity
So far, we have shown that TGF is a major T cell suppressor molecule from PR and that plateletspecific deletion of gp96 (which functionally deletes GARP) improves ACT of cancer. These fortuitous observations suggest that platelet-specific GARP plays critically negative roles in antitumor T cell immunity. This hypothesis was next addressed by comparing the efficacy of ACT of melanoma in WT, Plt-TGF1 KO , and Plt-GARP KO recipient mice (Fig. 6 ). B16-F1 melanomas were established in either WT or KO mice, followed by lymphodepletion with cyclophosphamide (Cy) on day 9, and the infusion of ex vivo activated Pmel T cells on day 10 (Fig. 6A ). Tumors were controlled much more efficiently in the Plt-GARP KO mice compared with WT mice (Fig. 6A) . This was associated with enhanced persistence (Fig. 6B) and functionality of Pmel cells in the peripheral blood of Plt-GARP KO mice (Fig. 6 , C and D). In contrast, Plt-TGF1 KO mice, whose platelets express GARP and remain capable of activating TGF, did not have improved control of tumors (Fig. 6D) . The generality of these findings was next studied in the MC38 colon carcinoma system, given that the growth of this transplantable tumor in syngeneic mice undergoes both CD4-and CD8-mediated immune pressure (38, 39) . The growth of MC38 was significantly diminished in Plt-GARP KO mice compared with WT mice (Fig. 7, A to C) . The MC38-bearing Plt-GARP KO mice had reduced serum levels of active TGF (Fig. 7D ).
Staining for p-Smad2/3 in MC38 tumor sections demonstrated a remarkable attenuation of TGF signaling in MC38 cells in Plt-GARP KO mice (Fig. 7 , E and F). This was associated with reduction of both systemic myeloid-derived suppressor cells (Fig. 7G ) and tumor-infiltrating T reg cells in Plt-GARP KO mice (Fig. 7H) . Together, this demonstrates that platelets are the commanding source of TGF activity in the tumor microenvironment and that they exert potent immunosuppressive effects on antitumor immunity via GARP-TGF. Correlation between LA concentration and cytokine production was established using Spearman's correlation coefficient. Difference between groups in (C) was tested by two-tailed independent Student's t test.
Antiplatelet pharmacological agents potentiate ACT of cancer
To establish the clinical relevance of the suppressive effect of platelets on antitumor immunity, we sought to inhibit platelets pharmacologically.
The results so far suggest that antiplatelet (AP) pharmacological agents can be exploited for enhancing cancer immunotherapy. This possibility was addressed using Pmel adoptive therapy of B16 melanoma (40) (41) (42) . B16-F1 melanomas were established in C57BL/6 mice after subcutaneous injection on day 0, followed by lymphodepletion with Cy on day 7, and infusion of ex vivo primed Pmel cells on day 8 (29), along with AP agents: aspirin and clopidogrel (43) . Aspirin and clopidogrel inhibit platelet activation by blocking cyclooxygenase and ADP receptors, respectively. Cy alone failed to control tumors, and the additional AP also had no antitumor effects in this model (Fig. 8A, left) . Melanoma was controlled well with T cells plus Cy for about 1 month, but most mice eventually relapsed. In contrast, AP agents plus adoptive T cell transfer were highly effective against B16-F1, with relapse-free survival of most mice beyond 3 months (Fig. 8A, right) . As a further proof, antigen-specific T cells were sustained at higher numbers in the blood, inguinal lymph nodes (ILNs), and spleens of mice receiving concurrent AP therapy and ACT (Fig. 8B) . AP agents conferred no benefit when the transferred T cells lacked IFN (Fig. 8C) or when anti-IFN neutralization antibodies were administered (Fig. 8D) .
DISCUSSION
The role of platelets in promoting cancer invasion has been previously observed (44, 45) . Multiple mechanisms have been attributed to this phenomenon including the promotion of angiogenesis (46) and stimulating epithelial-mesenchymal cell transition (9) . However, the direct contribution of platelets to anticancer immunity has not been well described despite the emerging appreciation of the cross-talk between platelets and the host immunity. The current study uncovers that platelets directly dampen T cell function both in vitro and in vivo. Furthermore, we demonstrated that the PR suppresses both CD4 + and CD8 + T cells mostly via TGF and, to a lesser extent, through lactate. It is intriguing that both lactate and TGF are enriched in the tumor microenvironment, whose source so far has been attributed mostly to cancer cells and other stromal cells (32, 47) . This study revealed that platelet-related TGF activation contributes dominantly to this immunosuppressive pool in cancer via cell surface TGF-docking receptor GARP. This conclusion is supported by enhanced tumor-specific T cell immunity in mice with plateletspecific deletion of GARP or its critical molecular chaperone gp96. Platelets are known to respond to tissue injury and infection. Upon activation, platelets self-aggregate and release a variety of soluble factors to promote tissue homeostasis (48) . Multiple molecules in the PR have immunomodulatory properties (2, 23) . We identified TGF and lactate to be the major mediators. Platelet contribution to extracellular TGF can be accomplished through the release of prestored TGF in the cytoplasmic granules or via the ability of surface GARP on platelets to snatch and bind TGF from nonplatelet sources. Our study demonstrates that platelet-intrinsic GARP plays the most dominant role in activating TGF and thus likely contributes significantly to the immunosuppressive molecular hallmarks in the cancer microenvironment. Platelets are known to express GARP constitutively and to up-regulate its expression upon activation. The other cells that are known to express GARP are T reg cells. We found that conditional deletion of GARP from T reg cells is not as effective as platelet-specific KO of GARP in supporting ACT ( fig. S10 ). Future studies are necessary to understand the roles and mechanisms of platelets broadly and the GARP-TGF axis specifically in regulating the biology of endogenous T cells in the tumor microenvironment such as differentiation and functionality.
There have been inconsistent reports on the systemic TGF level as a reliable biomarker for cancer, inflammation, and other conditions (49) (50) (51) . Consistent with the literature, we found that active TGF level is low in the plasma; however, after platelet activation and coagulation, serum active TGF level increased significantly. It has been unclear where active TGF in the serum comes from and what is the underlying mechanism of activation. The current study has resolved these long-standing puzzles. By genetically deleting GARP or TGF1 from platelets selectively, we have now reached several important conclusions: (i) Platelet-specific GARP is responsible for TGF activation because little active TGF can be detected in the sera of mice with platelet-specific deletion of either GARP or gp96; (ii) LTGF in the blood (both serum and plasma) is primarily supplied by platelets as revealed by platelet-specific TGF1 KO mice and platelet depletion studies; and (iii) the serum level of active TGF depends on the cell surface GARP-TGF complex, not the total level of soluble LTGF. Such evidence derived from the fact that, although plateletspecific TGF1 KO mice have drastically reduced soluble LTGF1 in the serum, they remain capable of making a comparable level of active TGF.
Consistent with the genetic studies, pharmacological platelet inhibitors were found to be effective in potentiating ACT of melanoma. It is also possible that platelet inhibitors may have other antitumor mechanisms, such as blocking angiogenesis and immunosuppressive prostaglandins (52) , which contribute to their antitumor activity. Notwithstanding, our work demonstrated that the AP agents alone do not have significant antitumor activity in our model. In addition, the improved antitumor effect was abolished when IFN was removed from the system, demonstrating that platelet inhibition promotes antitumor efficacy via an immunologically based mechanism. Given the clinical availability of multiple platelet inhibitors targeting distinct pathways of platelet activation, we hope that our study will catalyze a systematic effort to optimize cancer immunotherapy by simultaneously blocking platelets and immune checkpoint molecules in prospective clinical trials. Platelets have also been shown to play positive roles in the homing of T cells to sites of inflammation, to mediate a positive feedback loop of T cell recruitment through T cell activation via platelet CD40 (14) , and to promote liver cancer induced by dysfunctional liverdirected T cell responses (53) . The complexity of the roles of platelets in the tumor microenvironment is also illustrated by the finding that platelets can be extensively educated by tumor cells to uptake tumorassociated biomolecules such as RNAs (54) . However, our work strongly indicates that the net effect of platelets in cancer patients is to promote immune evasion of cancer. Physiologically, cancer represents a chronic nonhealing wound, whose progression and metastasis are inevitably accompanied by vascular endothelial damage and local exposure to multiple platelet activators (1, 48) . Our study thus suggests that cancer hijacks the tissue-repairing and hemostatic functions of platelets to suppress antitumor T cell immunity. A combination therapy with AP agents and immunotherapeutical modalities may thus represent a new paradigm for rational treatment of cancer in the future.
Last, although this study uncovers major suppressive molecules in the PR in an unbiased approach, such molecules were identified using in vitro experiments and translated to in vivo models using a hypothesis-driven approach. For example, TGF was identified as a major suppressive molecule secreted by platelets and this was validated in tumor mouse models. Although TGF was shown to be of biological relevance, it remains possible that, in vivo, the PR has a different composition and molecules other than TGF could play stronger roles. and not yet standard of care. Our mouse models are based on adoptive T cell transfer and not checkpoint inhibition, so understanding these differences in immunological therapies is important when designing future studies.
MATERIALS AND METHODS
Study design
In this study, an unbiased approach was used to identify the major T cell suppressors in the PR. This was achieved by fractionating the releasate as described below, screening for the active fractions, and subsequently identifying the active molecules. End points for in vitro experiments included T cell proliferation, blastogenesis, and cytokine production and activation markers. The clinical relevance of the in vitro findings was investigated in vivo. For in vivo experiments, each group contained between 4 and 10 mice; this provided enough power and validity to detect biologically relevant phenomena while ensuring the use of minimal numbers of mice necessary as per the guidelines of the Medical University of South Carolina (MUSC) Institutional Animal Care and Use Committee. Commercially obtained mice were randomly assigned to different groups in each experiment. For in house-bred, genetically engineered mice, littermates were assigned for comparison groups. Efficacy end points for in vivo experiments were tumor size, T cell engraftment, and cytokine secretion. Mice were sacrificed when they showed signs of severe moribund disease. Measurement techniques for in vitro and in vivo experiments are indicated accordingly for each experiment. All experiments were performed at least two times. Numbers of key experiments were indicated in the figure legend. Blinding was not feasible for most of the in vitro experiments and was not critical because data collection was mostly through objective measures such as flow cytometry. The surgical pathologist scoring immunohistochemical (IHC) stains was blinded to the identity of the samples. For in vivo experiments, researchers were blinded because genetically modified mice are not readily identifiable, as their outer appearances are comparable and they share the same cages. In Fig. 3 , blinding was maintained for the CD4 T H 17 adoptive transfer experiment, but not the CD8 transfer one. , IFN KO Pmel cells; n = 4 to 10 per group). (D) C57BL/6 mice were inoculated with B16-F1 sub cutaneously on day 0. Mice were lymphodepleted with Cy on day 9, followed by adoptive transfer of activated Pmel cells on day 10. IFN-neutralizing antibody (clone XMG1.2, BioXCell) was delivered intraperitoneally at 100 g per mouse every other day starting on day 11 until sacrifice. AP were given as described in (A) (n = 4 to 8 per group). Repeated-measures two-way ANOVA was used to compare the tumor growth curves in (A), (C), and (D). Kaplan-Meier curves and log-rank tests were used for relapse-free survival analysis. Two-tailed independent Student's t test was used in (B). Data are means ± SEM.
Mice
Platelet-specific Hsp90b1 KO mice were generated by crossing Pf4-cre mice (55) 
Ex vivo stimulation of tumor-draining lymph nodes
ILNs from tumor-bearing mice were isolated, mashed in cold phosphate-buffered saline (PBS), and filtered. One million cells per well were cultured in 96-well plates for 4 hours in the presence of phorbol 12-myristate 13-acetate (PMA) (500 ng/ml) and ionomycin (1.5 g/ml), or hgp100 peptide (Lys-Val-Pro-Arg-Asn-Gln-AspTrp-Leu, 25-33) (5 g/ml) for melanoma-draining lymph nodes. Brefeldin A (BD Biosciences) was added to the cells in all experiments.
Preparation of releasate from activated platelets
Mice were anesthetized, and blood was withdrawn to a 5-ml tube containing another 0.5 ml of acid citrate dextrose (ACD) buffer [39 mM citric acid, 75 mM sodium citrate, 135 mM dextrose, and prostaglandin E 1 (1 g/ml) (pH 7.4)]. Samples were centrifuged for 10 min at 100g, and the upper layer of platelet-rich plasma was collected. Platelets were washed twice with citrate washing buffer [128 mM NaCl, 11 mM glucose, 7.5 mM Na 2 HPO 4 , 4.8 mM sodium citrate, 4.3 mM NaH 2 PO 4 , 2.4 mM citric acid, 0.35% bovine serum albumin, and prostaglandin E 1 (50 ng/ml) (pH 6.5)], then resuspended in RPMI 1640, enumerated by a blood cell counter, and diluted to a final concentration of 1 × 10 8 /ml. Purified platelets were incubated with thrombin (1 IU/ml) for 45 min at 37°C (125 rpm). Stimulated platelets were sedimented by centrifugation at 3200g for 15 min, and supernatant was collected. Microvesicles (MVs) were collected by centrifugation at 25,000g and resuspension in PBS in the same volume as the original PR volume. For human platelet secretome, platelets from healthy donors were obtained from the blood bank at MUSC, resuspended in ACD buffer at room temperature, and then activated as above.
Size-based and anion exchange fractionation PR fractionation was carried out using a Pharmacia Akta-fast performance liquid chromatography system, and columns were purchased from GE Healthcare. The first fractionation was based on size by loading PR onto a Superdex 200 column and eluting with PBS or RPMI 1640 (Gibco). The active fractions were pooled and dialyzed with phosphate buffer (20 mM; pH 7.2). The resulted material was then loaded onto a diethylaminoethyl (DEAE) column and eluted with a linear gradient of NaCl from 0 to 1 M.
NMR-based metabolite profiling
Human PR was prepared at concentrations of 2 × 10 9 /ml and fractionated by size exclusion chromatography, followed by anion exchange chromatography. Fractions were eluted with sodium phosphate buffer (pH 7.0; 20 mM final concentration) containing sodium 3-trimethylsilyl-2,2,3,3-d 4 -propionate (TSP; 0.1 mM final concentration) and 10% D 2 O. NMR data were collected at 298 K on a Bruker Avance III 600 MHz NMR spectrometer (Bruker BioSpin Inc.) equipped with a 5-mm cryogenically cooled QCI-inverse probe. Solvent suppression was achieved using the excitation sculpting scheme (57) . Typically, one-dimensional (1D) 1 H NMR spectra with a 7-s recycle delay were acquired with a total of 128 transients in addition to four dummy scans. Real data points (32, 768) were collected across a spectral width of 12 parts per million (ppm) (acquisition time, 2.27 s). Data were zero-filled to twice the original data set size, manually phased, and automatically baseline-corrected using TopSpin 3.1 software (Bruker BioSpin Inc., Billerica, MA), and a 1.0-Hz line-broadening apodization was applied before spectral analysis. The singlet produced by the known quantity of the TSP methyl groups was used as an internal standard for chemical shift referencing (set to 0 ppm) and quantification.
Metabolite assignments were established after comparison of chemical shifts and spin-spin couplings with reference spectra as implemented in the Chenomx NMR Suite (Chenomx Inc., Edmonton, Alberta, Canada) profiling software (version 7.72). Specifically, quantification was achieved using the Chenomx 600 MHz metabolite library (version 8). Confirmatory 1D 31 P and 2D 1 H, 13 C-multiplicity-edited heteronuclear single quantum correlation spectra with adiabatic 13 C inversion, refocusing, and decoupling were recorded for selected PR fractions to enhance metabolite identification by comparison of 13 C chemical shifts with the biological magnetic resonance data bank. Concentration of LA was then quantified by an l-lactate assay kit (Eton Bioscience).
In vitro T cell culture suppression assay of PR
CD4
+ and CD8 + T cells were purified using magnetic beads to a purity of ≥95%. Cells (1 × 10 5 ) were cultured in 96-well plates precoated with anti-CD3 antibody (3 g/ml) in the presence of IL-2 (100 U/ml) and soluble anti-CD28 (2 g/ml), together with either media or PR. On day 3 of culture, T cells were stimulated with PMA (500 ng/ml)/ionomycin (1.5 g/ml) or hgp100 peptide 25-33 (5 g/ ml) for 4 hours in the presence of GolgiPlug (BD Biosciences), followed by staining for relevant markers. TGF receptor signaling was blocked using the combination of an ALK5 inhibitor (SB431542, Selleckchem) at 20 M and anti-TGF antibody (clone MAB1835, R&D Systems) at 2 g/ml. LA activity was inhibited by blocking the monocarboxylate transporter using -cyano-4-hydroxycinnamic acid (C2020, Sigma-Aldrich). For carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution assays, cells were labeled with 5 M CFSE for 10 min at room temperature before culture on day 0. Flow cytometry was then performed, and the data were analyzed and displayed with FlowJo software. Suppression index by PR was calculated as percentage of undivided cells treated with a given fraction of PR/ percentage of undivided cells in the control media.
Adoptive T cell therapy
Treatment of B16-F1 melanoma by adoptive transfer of ex vivo activated Pmel T cells was done as described previously (29) . To test the effect of AP agents on ACT, we administered clopidogrel by oral gavage 3 days after T cell transfer and then every 48 hours until day 25. Aspirin was administered through drinking water (150 mg/liter) starting 2 days before T cell transfer and was replaced every 48 hours afterward. For TRP1 T H 17 T cell therapy, single-cell suspensions of splenocytes from Rag1 −/− TRP1 mice (27) were seeded with irradiated C57BL/6 splenocytes pulsed with TRP1 106-130 peptide (SGHNC-GTCRPGWRGAACNQKILTVR; American Peptide). To obtain T H 17-polarized cells, we added recombinant human IL-6 [100 ng/ ml; National Institutes of Health (NIH)], TGF1 (30 ng/ml; BioLegend), IL-1 (10 ng/ml; Shenandoah), and anti-IL-4 and anti-IFN antibodies (10 g/ml; BioXCell) to the cultures. On the second day of culture, complete medium containing recombinant human IL-2 and IL-23 (40 ng/ml; PeproTech) was added. Where appropriate, human PR was added at 100% on days 0, 2, and 4. Cells were cultured for 5 days before experimentation. C57BL/6 mice were injected subcutaneously with 4 × 10 5 B16-F10 melanoma cells and treated 10 days later with TRP1-specific CD4 + T cells. Recipient mice were lymphodepleted using 5-gray total body irradiation on the day before cell transfer. Tumor growth was measured using calipers, and the products of the perpendicular diameters were recorded. In some experiments, IFN-neutralizing antibody (clone XMG1.2, BioXCell) or isotype control antibody was administered via intraperitoneal injection at 100 g per mouse every other day starting on day 12 until sacrifice (58) . The adoptive T cell transfer experiment with Ifng KO Pmel-1 cells was done identically as above except that Pmel cells were isolated from Ifng KO Pmel-1 mice (59). For some experiments, adoptive transfer was supplemented with exogenous IL-2-anti-IL-2 complexes on days 0, 2, 4, and 6 after transfer in the absence of lymphodepletion (60) . Briefly, 1.5 g of human IL-2 (National Cancer Institute Biological Resources Branch Preclinical Repository) was mixed with 7.5 g of anti-IL-2 monoclonal antibody (clone 5355, R&D Systems) for 15 min at room temperature. Cytokine complexes were administered via intraperitoneal injections.
Platelet depletion and serum collection for TGF ELISA WT mice were given one dose of rabbit anti-mouse thrombocyte polyclonal sera (1:40, Cedarlane) at 500 l per mouse intraperitoneally in sterile-filtered PBS. Blood was collected at 0, 24, 48, and 72 hours. Serum was harvested via coagulation and centrifugation (12,000g).
Measurement of TGF via ELISA
Mouse serum or plasma samples were collected by pricking the lateral tail vein. Capture ELISA for TGF1 was performed according to the manufacturer's instructions (BioLegend). Total TGF1 was measured after acidic activation using 1 M HCl for 10 min at room temperature.
Activation of human T cells
Human samples were isolated from buffy coats (Pennsylvania Plasma). CD8 + T cells were positively enriched from human peripheral blood mononuclear cells, followed by negative isolation of CD4 + T cells using magnetic isolation kits (Invitrogen). Cells were then stimulated with anti-CD3/anti-ICOS beads (Dynal) at 10:1 T cell/bead ratio for 4 days. IL-2 (100 IU/ml; NIH) was added to the T cell cultures. Human PR was added on day 0 and every other day thereafter. Cells were assayed on day 7 for cytokine production and phenotype.
MC38 model
MC38 tumor cells were obtained from Y.-X. Fu (University of Texas Southwestern Medical Center). WT or Plt-GARP KO mice were injected in the right flank with 1 × 10 6 MC38 colon cancer cells. Tumor size was measured with digital caliper kinetically. Tumor-infiltrating lymphocytes were isolated from fresh primary tumors by density gradient after single-cell suspensions were made with mechanical dissociation and enzymatic digestion (deoxyribonuclease and collagenase).
Immunohistochemistry
For p-Smad2/3 stain on fresh-frozen MC38 tumors, 5-m tumor sections were fixed with 4% paraformaldehyde followed by incubation with 3% H 2 O 2 . To minimize nonspecific staining, we incubated the sections with the appropriate animal serum for 20 min at room temperature, followed by incubation with primary anti-p-Smad2/3 antibody (EP823Y, Abcam) overnight at 4°C. Staining with secondary antibodies (Vectastain ABC Kit) was then performed before development using DAB substrate (SK-4100, Vector Labs). The staining intensity of p-Smad2/3 was graded as follows, with the sample identity blinded: 0, negative; 1, faint; 2, moderate; 3, strong but less intense than 4; 4, intense.
Statistical analysis
Two-sided, two-sample Student's t tests were used for all comparisons involving continuous dependent variables and categorical independent variables using Excel software. The variances were compared between groups using an F test. The Student's t test was then implemented assuming equal or unequal variances (i.e., if the F test P value was less than 0.05, then unequal variances were assumed). For tumor curves, two-way repeated-measures analysis of variance (ANOVA) was used. For dose-response correlations between continuous dependent and independent variables in Figs. 2 and 4, Spearman's rankorder correlation test was used to determine rho (). Kaplan-Meier curves were compared using log-rank tests. Error bars represent SEM. NS denotes statistically nonsignificant difference.
SUPPLEMENTARY MATERIALS
immunology.sciencemag.org/cgi/content/full/2/11/eaai7911/DC1 Table S1 . Source data for all the figure panels with small n (n < 20). . Immune suppression by PR is independent of TCR signaling and specific to lymphocytes. Fig. S4 . T cell-suppressive function of the whole PR is significantly, but not completely, neutralized by blocking TGF pathway. Fig. S5 . A small-molecular weight, heat-stable, proteinase K-resistant T cell-suppressive fraction is shared between human and mouse PRs. 
